News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
686,303 Results
Type
Article (39092)
Company Profile (279)
Press Release (646932)
Section
Business (203878)
Career Advice (1992)
Deals (35364)
Drug Delivery (86)
Drug Development (80820)
Employer Resources (168)
FDA (16093)
Job Trends (14805)
News (344583)
Policy (32443)
Tag
Academia (2531)
Alliances (49111)
Alzheimer's disease (1239)
Approvals (16026)
Artificial intelligence (141)
Bankruptcy (352)
Best Places to Work (11548)
Biotechnology (200)
Breast cancer (135)
Cancer (1145)
Cardiovascular disease (103)
Career advice (1660)
Cell therapy (240)
Clinical research (64354)
Collaboration (407)
Compensation (211)
COVID-19 (2533)
C-suite (101)
Data (1175)
Diabetes (157)
Diagnostics (6156)
Earnings (84844)
Employer resources (146)
Events (109718)
Executive appointments (326)
FDA (16661)
Funding (372)
Gene therapy (182)
GLP-1 (581)
Government (4327)
Healthcare (18685)
Infectious disease (2619)
Inflammatory bowel disease (108)
Interviews (308)
IPO (16311)
Job creations (3624)
Job search strategy (1417)
Layoffs (414)
Legal (7854)
Lung cancer (174)
Manufacturing (179)
Medical device (13187)
Medtech (13192)
Mergers & acquisitions (19153)
Metabolic disorders (410)
Neuroscience (1527)
NextGen Class of 2024 (6500)
Non-profit (4464)
Northern California (1539)
Obesity (234)
Opinion (179)
Patents (108)
People (56314)
Phase I (19994)
Phase II (28343)
Phase III (21133)
Pipeline (475)
Postmarket research (2555)
Preclinical (8505)
Radiopharmaceuticals (236)
Rare diseases (228)
Real estate (5890)
Regulatory (21564)
Research institute (2311)
Resumes & cover letters (349)
Southern California (1335)
Startups (3562)
United States (13939)
Vaccines (553)
Weight loss (169)
Date
Today (108)
Last 7 days (381)
Last 30 days (3263)
Last 365 days (35503)
2024 (33365)
2023 (40074)
2022 (51174)
2021 (55716)
2020 (54095)
2019 (46547)
2018 (35022)
2017 (32109)
2016 (31485)
2015 (37554)
2014 (31321)
2013 (26345)
2012 (28571)
2011 (29263)
2010 (27330)
Location
Africa (713)
Arizona (193)
Asia (37172)
Australia (6066)
California (3449)
Canada (1336)
China (268)
Colorado (151)
Connecticut (159)
Europe (79599)
Florida (481)
Georgia (122)
Illinois (351)
Indiana (204)
Kansas (96)
Maryland (595)
Massachusetts (2711)
Michigan (160)
Minnesota (277)
New Jersey (992)
New York (996)
North Carolina (714)
Northern California (1539)
Ohio (142)
Pennsylvania (866)
South America (1091)
Southern California (1335)
Texas (495)
Utah (92)
Washington State (371)
686,303 Results for "neuron23 inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease
November 19, 2024
·
7 min read
Press Releases
Neuron23 Announces Usage of Roche’s Digital Biomarker and Device in Parkinson’s Disease Clinical Trial
November 19, 2024
·
4 min read
Business
Neuron23 Appoints Andrew Yost, MBA, as Chief Business Officer
Neuron23™ Inc. today announced the appointment of Andrew Yost, MBA, as the company’s chief business officer (CBO).
August 22, 2023
·
3 min read
Drug Development
Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinson’s Disease
Neuron23™ Inc. today announced that the Company recently initiated dosing in a Phase 1 clinical trial of NEU-723 for the treatment of Parkinson’s disease.
February 7, 2023
·
4 min read
Business
Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
Neuron23™ Inc. and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease.
September 14, 2022
·
7 min read
Business
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and Neuron23 Inc. today announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease.
September 14, 2022
·
7 min read
Business
Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer
Neuron23™ Inc. today announced the appointment of Sam Jackson, M.D., MBA, as the company’s first chief medical officer (CMO).
April 12, 2022
·
2 min read
Biotech Bay
$100M Richer, Neuron23 Introduces LRRK2 inhibitor for Parkinson’s
Neuron23 announced today that it closed a $100 million Series C financing round led by SoftBank Vision Fund 2.
March 30, 2022
·
3 min read
·
Hayley Shasteen
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Press Releases
BioVie Inc. Announces Proposed Public Offering
September 24, 2024
·
5 min read
1 of 68,631
Next
